

MENDUS TO PARTICIPATE IN INVESTOR AND INDUSTRY CONFERENCES IN FEBRUARY

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming investor and industry conferences:

BIO Capital 2025

Amsterdam, The Netherlands, February 5 – 6, 2025

Mendus CEO Erik Manting will attend

Cell & Gene Therapy Manufacturing Summit 2025

Basel, Switzerland, February 12 – 14, 2025

Mendus CTO Leopold Berteau will hold a presentation about establishing large-scale manufacturing for Mendus' lead program vididencel and participate in a panel discussion about challenges and solutions in the manufacturing and supply chain of cell therapy products

For more information, please see [Cell & Gene Therapy Manufacturing Summit 2025](#)

Biologics Manufacturing Germany

München, Germany, February 18 – 19, 2025

Mendus CTO Leopold Berteau will hold a presentation about establishing large-scale manufacturing for Mendus' lead program vididencel and participate in a panel discussion about evolving collaboration models between biopharmaceutical companies and manufacturing organizations

For more information, please see [Biologics Manufacturing Germany](#)

For more information, please contact:

Erik Manting

Chief Executive Officer

E-mail: ir@mendus.com

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life.

We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>